Lantern Pharma Inc (LTRN) - Total Assets
Based on the latest financial reports, Lantern Pharma Inc (LTRN) holds total assets worth $8.60 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Lantern Pharma Inc - Total Assets Trend (2018–2025)
This chart illustrates how Lantern Pharma Inc's total assets have evolved over time, based on quarterly financial data. Also see LTRN company net worth for the company's overall valuation and market capitalisation.
Lantern Pharma Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Lantern Pharma Inc's total assets of $8.60 Million consist of 97.9% current assets and 2.1% non-current assets. Review LTRN total debt and obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 40.1% |
| Accounts Receivable | $30.00K | 0.3% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how Lantern Pharma Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See current stock price of Lantern Pharma Inc for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Lantern Pharma Inc's current assets represent 97.9% of total assets in 2025, a decrease from 99.0% in 2018.
- Cash Position: Cash and equivalents constituted 40.1% of total assets in 2025, down from 99.0% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 0.3% of total assets.
Lantern Pharma Inc Competitors by Total Assets
Key competitors of Lantern Pharma Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Lantern Pharma Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.96 | 3.52 | 42.75 |
| Quick Ratio | 1.96 | 3.52 | 42.75 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $4.14 Million | $12.32 Million | $74.55 Million |
Lantern Pharma Inc - Advanced Valuation Insights
This section examines the relationship between Lantern Pharma Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 9.74 |
| Latest Market Cap to Assets Ratio | 1.98 |
| Asset Growth Rate (YoY) | -56.8% |
| Total Assets | $11.04 Million |
| Market Capitalization | $21.86 Million USD |
Valuation Analysis
Above Book Valuation: The market values Lantern Pharma Inc's assets above their book value (1.98x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Lantern Pharma Inc's assets decreased by 56.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Lantern Pharma Inc (2018–2025)
The table below shows the annual total assets of Lantern Pharma Inc from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $11.04 Million | -56.84% |
| 2024-12-31 | $25.57 Million | -41.41% |
| 2023-12-31 | $43.65 Million | -25.82% |
| 2022-12-31 | $58.84 Million | -20.44% |
| 2021-12-31 | $73.95 Million | +263.22% |
| 2020-12-31 | $20.36 Million | +1321.19% |
| 2019-12-31 | $1.43 Million | +218.47% |
| 2018-12-31 | $449.83K | -- |
About Lantern Pharma Inc
Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1a clinical trial for the treatment of advanced or metastatic solid tumors, or unresectable or recurrent GBM, solid tumor,… Read more